Improving cancer immunotherapy by targeting specific immune cells
Targeting GPR84 to Overcome Macrophage Mediated Resistance to Immunotherapy
This study is looking at how certain immune cells in tumors can make cancer treatments less effective, and it hopes to find ways to change these cells so they help fight cancer instead, which could improve treatment outcomes for people with bladder cancer and other types of tumors.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-11082295 on NIH RePORTER |
What this research studies
This research investigates how certain immune cells, specifically tumor-associated macrophages (TAMs), contribute to the resistance against cancer immunotherapy. By understanding the molecular signals that influence these macrophages, the study aims to develop strategies to reprogram them from promoting tumor growth to supporting anti-tumor immune responses. The approach focuses on the role of fatty acid signals in this transformation, which could enhance the effectiveness of existing immunotherapy treatments for cancer patients. Patients with bladder cancer and other tumors may benefit from insights gained through this research.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with bladder cancer or other tumors who are undergoing or considering immunotherapy.
Not a fit: Patients with tumors that do not involve macrophage-mediated resistance or those not receiving immunotherapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved outcomes for cancer patients receiving immunotherapy by overcoming resistance mechanisms.
How similar studies have performed: Other research has shown promising results in reprogramming immune cells to enhance cancer treatment, indicating that this approach has potential for success.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Xin, Gang — Ohio State University
- Study coordinator: Xin, Gang
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.